PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN ...

Core Insights - Telix Pharmaceuticals has received recognition for its investigational PET agent TLX250-CDx in updated clinical guidelines for molecular imaging of renal masses, marking a significant advancement in precision medicine for renal cancer [1][5][6] Group 1: Clinical Guidelines and Implications - The updated guidelines from SNMMI, EANM, and ACNM highlight the potential of molecular imaging for risk stratification of indeterminate renal masses, which can enhance patient management decisions [2] - The guidelines endorse TLX250-CDx PET as a well-tolerated and accurate method for non-invasive identification of clear cell renal cell carcinoma (ccRCC), contrasting with traditional F-FDG PET methods that have high renal excretion rates [3][4] Group 2: Clinical Trial Data - Data from Telix's pivotal Phase 3 ZIRCON trial demonstrated that TLX250-CDx met all primary and secondary endpoints, achieving a sensitivity of 86%, specificity of 87%, and a positive predictive value (PPV) of 93% for ccRCC, including small lesions [4][6] - TLX250-CDx specifically binds to carbonic anhydrase IX (CAIX), a target protein present in over 95% of ccRCC cells, resulting in high tumor-to-background ratios and consistent imaging results [4][6] Group 3: Company Statements and Future Outlook - Experts, including Professor Brian Shuch, emphasize that the inclusion of TLX250-CDx PET in clinical guidelines represents a shift towards precision medicine, providing clinicians with improved diagnostic tools for individualized treatment planning [5] - Telix's CEO, Kevin Richardson, noted that this endorsement by a global expert panel is expected to drive adoption and implementation of TLX250-CDx in clinical workflows, ultimately enhancing patient outcomes [5]

WILMINGTON, Del., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, November 4, 2025. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 5. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://i ...

FRAUENFELD, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Aebi Schmidt Group (NASDAQ: AEBI) (“Aebi Schmidt” or the “Company”), a world-class specialty vehicles leader, today announced that its Board of Directors has declared a quarterly dividend, and the Company will host its third quarter 2025 earnings conference call and webcast on November 13, 2025. Quarterly Dividend The Company’s Board of Directors has declared a continued quarterly cash dividend of $0.025 per share of common stock (CUSIP: H00501108). ...

Gogo will release its third quarter 2025 financial results before the market opens on November 6, 2025.Broomfield,CO., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Gogo Inc. (NASDAQ: GOGO), the leading global provider of broadband connectivity services for the business aviation, military, and government markets, announced today that it will release its third quarter 2025 financial results before the market opens on November 6, 2025. The Company will host a conference call with financial analysts on the same day at 8:3 ...

Core Insights - Plug Power Inc. has successfully deployed its GenDrive hydrogen fuel cell systems and GenFuel hydrogen infrastructure at Floor & Decor's distribution center in Frederickson, WA, marking a significant step in zero-emission material handling solutions for the retail sector [1][4] Group 1: Deployment Details - The Frederickson facility is equipped with a complete hydrogen ecosystem, powering 77 pieces of material handling equipment with a 10,000-gallon liquid hydrogen storage tank, vaporizers, compressors, and a high-capacity dispensing system [2] - The hydrogen fuel cell technology is expected to eliminate over 400 metric tons of CO₂e emissions annually, equivalent to avoiding the burning of approximately 45,000 gallons of gasoline [3] Group 2: Environmental Impact - The system produces only water vapor as a byproduct, which is captured and reused for facility operations, generating about 300 liters (approximately 80 gallons) of water per day for recapture [3] Group 3: Strategic Implications - This partnership demonstrates the reliability and performance of Plug's GenDrive systems in retail distribution environments and supports Floor & Decor's operational efficiency goals [4] - The success at the Frederickson site may lead to expanded hydrogen infrastructure, enhancing energy resilience during power outages and grid instability, while also allowing for scalability as operations grow [4] Group 4: Company Overview - Plug Power is a leader in the hydrogen economy, providing a fully integrated ecosystem that includes production, storage, delivery, and power generation [5] - The company has deployed over 72,000 fuel cell systems and 275 fueling stations, and is the largest user of liquid hydrogen, with operational hydrogen plants in Georgia, Tennessee, and Louisiana capable of producing 40 tons per day [6]

Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging TechnologyTORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a commercial-stage medical device company focused on intravascular imaging solutions, today announced that it will participate in the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference, taking place October 25 – 28, 2025, at the Moscone Center in San Francisco, California. Attendees will have the ...

RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) i ...

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (NASDAQ: MRX) today announced that it will release its fiscal 2025 third quarter results before market open on Thursday, November 6, 2025. The earnings release and supplementary materials will be available through the "Investors" section of the Marex website at https://ir.marex.com/. A conference call to discuss the results will take place at 9am ET the same day. If you would like to attend the live conference call you can access it here: https://e ...

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the markets open on Thursday, November 6th, 2025. An accompanying conference call and webcast will be condu ...